Given the importance of vascular endothelial growth factors (VEGFs) in angiogenesis, much attention has been focused on developing anti‐angiogenic receptor tyrosine kinase (RTK) inhibitors targeting the VEGFR signaling pathway to treat a variety of cancers by blocking tumor angiogenesis. The gene discussed is KDR; the disease is cancer.